John Oyler, BeiGene CEO (Paul Yeung/Bloomberg via Getty Images)
September 2, 2021 08:57 AM EDT
Pharma
FDA+

FDA ap­proves BeiGene's Brukin­sa in rare blood can­cer amid com­pa­ny's US ex­pan­sion plans

Kyle Blankenship

BeiGene has been any­thing but shy about its US ex­pan­sion plans cen­tered around blood can­cer drug Brukin­sa. To see those plans through, BeiGene will have …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Mi­crosoft-backed Enve­da rais­es $130M for drugs in I&I, obe­si­ty and oth­er ar­eas

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

As­traZeneca culls Phase 2 opi­oid use dis­or­der drug

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times